Bibliography

Export 16 results:
Filters: Author is Gruneir, A. and First Letter Of Keyword is C  [Clear All Filters]
M
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.